Physician profile
Mohammed Abubaker
NPI 1396733796
$218,447.31
in general payments reported to CMS, 2019-2025
47 companies · $3,095 in 2025
The $3,095 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $52K · 2021: $24K · 2022: $27K · 2023: $16K · 2024: $16K · 2025: $3,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $12K · Consulting Fee: $6,940 · Travel and Lodging: $889 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,787.50 |
| Food and Beverage | $11,944.77 |
| Consulting Fee | $6,940.00 |
| Travel and Lodging | $888.91 |
| Education | $108.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $74,374.14 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $35,112.72 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $21,868.81 | 2020-2025 | Acthar |
| Genzyme Corporation | $20,503.40 | 2019-2022 | |
| Janssen Biotech, INC. | $11,814.58 | 2019-2025 | Tremfya, Simponi Aria |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,934.02 | 2019-2023 | |
| Mallinckrodt Enterprises LLC | $8,822.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $8,334.06 | 2019-2025 | Orencia |
| Ucb, INC. | $6,425.24 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $4,446.54 | 2019-2023 | Krystexxa |
| Amgen INC. | $3,852.01 | 2019-2025 | Enbrel, Otezla, Evenity |
| Regeneron Healthcare Solutions, INC. | $3,748.63 | 2019 | |
| Janssen Global Services, LLC | $2,000.00 | 2021 | |
| Pfizer INC. | $1,156.84 | 2019-2025 | |
| Lilly USA, LLC | $950.76 | 2019-2024 | Taltz |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $657.65 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Astrazeneca Pharmaceuticals Lp | $594.35 | 2020-2025 | Saphnelo, Lokelma |
| Glaxosmithkline, LLC. | $535.25 | 2019-2025 | Benlysta, Nucala |
| Janssen Scientific Affairs, LLC | $529.50 | 2019-2022 | |
| Genentech USA, INC. | $450.46 | 2019-2025 | Actemra |
| Radius Health, INC. | $355.05 | 2019-2024 | Tymlos |
| Aurinia Pharma U.S., INC. | $281.27 | 2022-2025 | Lupkynis |
| Gilead Sciences, INC. | $237.26 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $223.85 | 2019-2021 | |
| Depuy Synthes Sales INC. | $223.73 | 2019-2020 | |
| Antares Pharma, INC. | $163.84 | 2019-2021 | |
| Sandoz INC. | $94.26 | 2023-2025 | Hyrimoz |
| Genentech, INC. | $91.85 | 2022 | |
| Arcutis Biotherapeutics, INC. | $81.92 | 2023 | |
| Medexus Pharma, INC. | $79.40 | 2020-2021 | |
| Celgene Corporation | $67.68 | 2019 | |
| Organon LLC | $55.50 | 2023-2024 | Renflexis |
| Sobi, INC | $50.94 | 2022-2024 | |
| Novo Nordisk INC | $48.64 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $43.03 | 2021-2022 | |
| Fidia Pharma USA INC. | $36.64 | 2021-2025 | Hymovis |
| Actelion Pharmaceuticals US, INC. | $34.11 | 2024-2025 | Opsumit, Uptravi |
| Almatica Pharma LLC | $27.64 | 2025 | Teriparatide |
| Invivyd INC | $24.24 | 2025 | Pemgarda |
| Abbott Laboratories | $19.49 | 2024 | Proclaim |
| Octapharma USA, INC. | $18.78 | 2023 | Octagam Immune Globulin (Human) |
| Mylan Institutional INC. | $17.72 | 2023 | |
| Orthogenrx INC. | $17.39 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.29 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.86 | 2021 | |
| Merck Sharp & Dohme LLC | $11.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Abubaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.